Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
根据最新的财务报表(Form-10K),WuXi Biologics (Cayman) Inc. 的总资产为 $56,977,净利润为 $3,356
WXXWY 的关键财务比率是什么?
WuXi Biologics (Cayman) Inc. 的流动比率是 3.75,净利 margin 为 17.97,每股销售为 $4.41。
WuXi Biologics (Cayman) Inc. 的收入按细分市场或地理位置如何划分?
WuXi Biologics (Cayman) Inc. 最大收入来源是 Biologics,在最近的收益报告中收入为 15,972,158,570。就地区而言, North America 是 WuXi Biologics (Cayman) Inc. 的主要市场,收入为 11,596,649,464。
WuXi Biologics (Cayman) Inc. 是否盈利?
是的,根据最新的财务报表,WuXi Biologics (Cayman) Inc. 的净利润为 $3,356